Search clinical trials for: Pegol-Sihematide

Total 241 results

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Unknown

Safety & Pharmacokinetics of Pegolsihematide for Treatment of Anemia Patient With Myelodysplastic Syndromes

Myelodysplastic Syndromes | Anemia

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With Chronic Kidney Disease on Dialysis

Chronic Kidney Diseases

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Unknown

Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis

Anemia | Dialysis | Chronic Renal Failure

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Active, not recruiting

Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With NDD-CKD

Non-Dialysis-Dependent Chronic Kidney Disease

China
Allergan

Completed

A Study to Evaluate Abicipar Pegol for Safety and Treatment Effect in Participants With Neovascular Age-related Macular Degeneration (AMD)

Macular Degeneration

United States
Novo Nordisk A/S

Active, not recruiting

A Research Study Investigating Nonacog Beta Pegol (N9-GP) for Treatment and Prevention of Bleedings in Chinese People With Haemophilia B (Paradigm9)

Haemophilia B

China
Novo Nordisk A/S

Enrolling by invitation

Adverse Event Data Collection From External Registries on Nonacog Beta Pegol

Haemophilia B

Netherlands, United Kingdom
Novo Nordisk A/S

Completed

Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B (paradigm™6)

Congenital Bleeding Disorder | Haemophilia B

Spain, United Kingdom, Australia, Taiwan, France, Malaysia, United States, Austria, Canada, Israel, Japan, Thailand, Algeria, Argentina
Novo Nordisk A/S

Enrolling by invitation

A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN

Haemophilia B

Canada, United Kingdom, Czechia, Germany, Greece, Austria, Belgium, Croatia, Denmark, Finland, Norway, Portugal
UCB Biopharma SRL

Enrolling by invitation

A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

United States, Argentina, Belgium, Bulgaria, Canada, Chile, Czechia, Germany, Greece, Hungary, Mexico, Poland, Romania, Serbia, Spain, Taiwan, Colombia, Italy, Korea, Republic of, Peru, Philippines
Allergan

Completed

Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Patients With Neovascular AMD

Macular Degeneration

United States
TME Pharma AG
German Federal Ministry of Education and Research

Completed

NOX-A12 First-in-human (FIH) Study

Autologous Stem Cell Transplantation

Germany
UCB Pharma

Withdrawn

Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas

Crohn Disease
Novo Nordisk A/S

Completed

Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B. (paradigm™5)

Congenital Bleeding Disorder | Haemophilia B

United States, Canada, United Kingdom, France, Malaysia, Brazil, Croatia, Germany, Italy, Japan, Taiwan
Novo Nordisk A/S

Completed

Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773 (paradigm™ 4)

Congenital Bleeding Disorder | Haemophilia B

United States, Netherlands, Austria, Spain, Germany, Macedonia, The Former Yugoslav Republic of, Taiwan, United Kingdom, Italy, Malaysia, Thailand, France, Greece, Russian Federation, Turkey, Japan, South Africa, Romania
Biogen

Completed

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB133 (Dapirolizumab Pegol) in Healthy Japanese and Caucasian Participants

Healthy Volunteers

United States
UCB Pharma

Completed

Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines

Rheumatoid Arthritis

United States
Novo Nordisk A/S

Enrolling by invitation

Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®

Haemophilia A

Japan
Novo Nordisk A/S

Completed

A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A (pathfinder™7)

Congenital Bleeding Disorder | Haemophilia A

United States, Netherlands, Spain, Germany, France, Denmark
UCB Pharma

Completed

Maintenance Study Including Re-induction Therapy for Patients Who Did Not Show a Clinical Effect in Study C87037 (NCT00291668)

Crohn's Disease

Japan
UCB Pharma SA

Completed

A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease (PRECiSE 4)

Crohn's Disease

United States, Australia, Austria, Belarus, Belgium, Bulgaria, Canada, Czechia, Denmark, Estonia, Germany, Hungary, Israel, Italy, New Zealand, Norway, Poland, Russian Federation, Serbia, Singapore, Slovenia, South Africa, Spain, Ukraine
UCB Pharma

Withdrawn

A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease

Crohn's Disease
Takeda
Affymax

Terminated

A Safety and Tolerability Study of Peginesatide in Anemic Cancer Patients Receiving Cytotoxic Chemotherapy.

Anemia

United States
Novo Nordisk A/S

Completed

Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B

Congenital Bleeding Disorder | Haemophilia B

United States, Sweden, Spain, Germany, United Kingdom, Denmark, France, Japan
UCB Pharma

Completed

Comparison Bioequivalence Study: Pre-filled Syringe (Reference) Versus Auto-injection Device (Test)

Healthy

France
University of Washington
University of Pennsylvania; UCB Pharma

Completed

Study of Cimzia for the Treatment of Ulcerative Colitis (UC CIMZIA)

Ulcerative Colitis

United States
UCB Pharma

Completed

A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)

Crohn's Disease
UCB Pharma

Completed

Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).

Crohn's Disease
Nathan Wei, MD, FACP, FACR:
University of California, San Diego

Completed

Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia)

Rheumatoid Arthritis

United States
UCB Pharma

Completed

Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease (COSPAR II)

Crohn's Disease

United States, Germany, Canada
Novo Nordisk A/S

Completed

Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients (paradigm™ 2)

Congenital Bleeding Disorder | Haemophilia B

United States, Netherlands, Germany, Macedonia, The Former Yugoslav Republic of, United Kingdom, Italy, Malaysia, Hungary, Thailand, France, Russian Federation, Turkey, Japan, South Africa, Canada
Atlanta Gastroenterology Associates
UCB Pharma

Unknown

Optimizing Cimzia in Crohn's Patients

Crohn's Disease

United States
UCB Biopharma SRL

Completed

A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice (CIMREAL)

Plaque Psoriasis

Belgium, Canada, Czechia, France, Germany, Greece, Italy, Spain, United Kingdom
UCB Pharma

Completed

A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis Subjects (PREDICT)

Rheumatoid Arthritis

United States
Shafran Gastroenterology Center
UCB Pharma

Completed

Assessment of Small Bowel Healing in Crohn's Disease Patients Treated With Cimzia Using Wireless Capsule Endoscopy

Crohn's Disease

United States
Novo Nordisk A/S

Completed

Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10) (Pathfinder10)

Haemophilia A

China
UCB Pharma

Completed

A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis

Rheumatoid Arthritis

United States, Canada, Belgium, Argentina, Israel, Bulgaria, Chile, Russian Federation, Australia, Czechia, Latvia, Ukraine, Croatia
Novo Nordisk A/S

Completed

Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B (paradigm™ 3)

Congenital Bleeding Disorder | Haemophilia B

United States, Netherlands, Austria, Spain, Germany, Macedonia, The Former Yugoslav Republic of, Taiwan, United Kingdom, Italy, Malaysia, Thailand, France, Greece, Turkey, Japan, South Africa, Romania
UCB Pharma

Completed

Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA) (MARVELOUS)

Rheumatoid Arthritis

Denmark, Netherlands, Poland, Sweden
UCB Pharma

Completed

Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study (CERTAIN)

Rheumatoid Arthritis

France, Poland, Germany, Austria, Italy
Bayer

Completed

Study to Compare How the Body Distributes and Excretes the Drugs Jivi (BAY 94-9027) and Adynovi in Patients With Severe Hemophilia A (Bleeding Disorder Resulting From a Lack of Blood Clotting Factor VIII)

Hemophilia A

Bulgaria
UCB Pharma

Completed

Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease (Welcome2)

Crohn's Disease

United States, France, Italy, United Kingdom, Belgium, Germany, Spain, Switzerland, Canada, Netherlands, Austria, Sweden
UCB Pharma

Completed

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (REALISTIC)

Rheumatoid Arthritis

United States, France, Italy, Germany, Spain, Canada, Netherlands
UCB Pharma

Completed

Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis

Psoriasis

France, Germany
UCB Pharma SA

Completed

A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] (PRECiSE 3)

Crohn's Disease

United States, Australia, Austria, Belarus, Belgium, Bulgaria, Czechia, Denmark, Estonia, Germany, Hungary, Israel, Italy, New Zealand, Norway, Poland, Russian Federation, Serbia, Singapore, Slovenia, South Africa, Spain, Ukraine, Canada and more
UCB Pharma

Completed

Bio-availability Comparison of Three Formulations of Certolizumab Pegol in Healthy Volunteers

Bioavailability Study on Healthy Volunteers

France
UCB Pharma

Completed

Evaluation of the Effects of Certolizumab Pegol on Semen Quality in Healthy Male Volunteers

Sperm Quality

Belgium
UCB Pharma

Completed

Mucosal Healing Study in Crohn's Disease (CD) (MUSIC)

Crohn's Disease

France, Germany, Belgium
Novo Nordisk A/S

Recruiting

An Observational Research Study of the Health of Joints in People With Haemophilia Taking the Medicine Esperoct

Haemophilia A

Canada
UCB Biopharma SRL

Completed

A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States

3

Subscribe